Rhodes Jason P's Form 4 filing
Dyne Therapeutics, Inc. (DYN) · filed May 6, 2026
- Accession no.
- 0001577014-26-000008
- Filed
- May 6, 2026
- Trade date
- May 4-6, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 12 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.94M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rhodes Jason PCIK 0001577014 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Common Stock | SSaleDisposed | −3,136 | $18.00 | −$56,448 | 1,574,270 | Indirect | |
| May 4, 2026 | Common Stock | SSaleDisposed | −6,241 | $18.00 | −$112,338 | 4,933,196 | Indirect | |
| May 4, 2026 | Common Stock | SSaleDisposed | −61 | $18.00 | −$1,098 | 8,450 | Indirect | |
| May 4, 2026 | Common Stock | SSaleDisposed | −2,466 | $18.00 | −$44,388 | 1,156,457 | Indirect | |
| May 5, 2026 | Common Stock | SSaleDisposed | −3,056 | $18.03 | −$55,099.68 | 1,571,214 | Indirect | |
| May 5, 2026 | Common Stock | SSaleDisposed | −6,081 | $18.03 | −$109,640.43 | 4,927,115 | Indirect | |
| May 5, 2026 | Common Stock | SSaleDisposed | −60 | $18.03 | −$1,081.8 | 8,390 | Indirect | |
| May 5, 2026 | Common Stock | SSaleDisposed | −2,403 | $18.03 | −$43,326.09 | 1,154,054 | Indirect | |
| May 6, 2026 | Common Stock | SSaleDisposed | −21,926 | $18.18 | −$398,614.68 | 1,549,288 | Indirect | |
| May 6, 2026 | Common Stock | SSaleDisposed | −43,621 | $18.18 | −$793,029.78 | 4,883,494 | Indirect | |
| May 6, 2026 | Common Stock | SSaleDisposed | −428 | $18.18 | −$7,781.04 | 7,962 | Indirect | |
| May 6, 2026 | Common Stock | SSaleDisposed | −17,244 | $18.18 | −$313,495.92 | 1,136,810 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.